Loblaw Advances Fleet Modernization With Five Hydrogen Fuel Cell Electric Vehicle Order
By Adriano Marchese
Loblaw is planning to buy five new hydrogen fuel cell electric vehicles as part of an effort to grow its zero-emission fleet.
The Canadian retailer said it has plans to purchase five Class 8 T680 vehicles Kenworth. The trucks will have a range of over 700 kilometers which will allow Loblaw to complete long-haul zero-emission deliveries.
These new trucks will join Loblaw's growing fleet of zero-emission vehicles, of which 35 are currently on order from various manufacturers.
Earlier in the year, the company began using its first two electric commercial class 8 day-cab vehicles to make short delivers from its Quebec-based distribution center to stores around Montreal.
Loblaw has committed to achieving net-zero carbon emissions across its enterprise by 2040, and its fleet plays largely in its efforts, and has current targets to electrify its fleet of short-haul day-cab trucks by 2023.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
May 25, 2023 07:36 ET (11:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track